Zonulin Receptor Antagonist · Tight Junction Protector · Protocol Guide
Larazotide: The Honest Gut Permeability Peptide Guide
Larazotide acetate (AT-1001) is a synthetic octapeptide that blocks the zonulin receptor on intestinal cells, preventing the tight-junction opening that drives leaky gut. Its human evidence is real but narrow: Phase 2 celiac disease trials. This guide explains what those trials found and where the evidence stops.
- FDA Status
- No approval, Phase 2 trials completed
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised
- Access
- 28 U.S. States
Our promise: Larazotide has more human trial data than most compounded peptides, but its best evidence is in celiac disease during a supervised gluten challenge, not in general leaky gut or chronic gut conditions. We state where the evidence is strong and where it becomes extrapolation.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed June 17, 2026.On this page
Section 01
What Larazotide Actually Is
Larazotide acetate, also known as AT-1001, is a synthetic octapeptide (eight amino acids) derived from the Zonula occludens toxin secreted by Vibrio cholerae. The natural toxin opens intestinal tight junctions to allow the bacteria to pass; larazotide was engineered to do the opposite. It occupies the receptor that the body's own permeability-regulating protein, zonulin, uses to signal those junctions to open. By sitting in that receptor without activating it, larazotide blocks the zonulin signal and keeps tight junctions closed.
The peptide was developed by Alba Therapeutics and subsequently acquired by 9 Meters Biopharma. It completed two Phase 2 trials in celiac disease, reaching 342 patients in the larger study, which makes it one of the most clinically evaluated oral peptides in the gut permeability space. It has not received FDA approval.
Larazotide is an oral capsule, not an injection. It works locally in the intestinal lumen with minimal systemic absorption. That local-action profile means the compound does not enter the bloodstream in meaningful quantities, which limits both its systemic effects and the safety concerns that come with most injectable compounds.
8
Amino acids in the larazotide acetate sequence
342
Patients enrolled in the Phase 2b celiac trial (Leffler 2015)
0.5 mg
Most-studied oral dose (three times daily before meals)
503A
Pathway for U.S. compounded access under physician prescription
Section 02
Who It Is Actually For
Larazotide is relevant to any patient whose primary complaint involves intestinal permeability. The strength of the evidence varies considerably by population.
| Profile | Primary Goal | Evidence Basis | Fit |
|---|---|---|---|
| Celiac disease, active gluten exposure | Reduce symptoms during accidental gluten ingestion | Phase 2 RCT (Kelly 2013): significant reduction in GI symptom severity during supervised gluten challenge. | Best Studied |
| Celiac disease, persistent symptoms on GFD | Reduce residual GI symptoms despite adherence to gluten-free diet | Phase 2b RCT (Leffler 2015): primary endpoint narrowly missed; secondary endpoints for abdominal pain and diarrhea were significant. | Randomized, Mixed Result |
| Non-celiac gluten sensitivity (NCGS) | Reduce gut symptoms triggered by gluten exposure | Mechanistically identical rationale to celiac. No randomized trial in NCGS specifically. | Plausible, Untrialed |
| Post-infectious gut permeability, SIBO, IBD | Restore tight junction integrity after gut insult | Zonulin is elevated in IBD and post-infectious states. No RCT for larazotide in these conditions. | Exploratory |
| General leaky gut or autoimmune permeability | Reduce systemic antigen load by tightening gut barrier | The mechanistic hypothesis is sound. Human trial evidence does not exist for this broader population. | Speculative |
Profile
Primary Goal
Evidence Basis
Fit
Profile
Primary Goal
Evidence Basis
Fit
Profile
Primary Goal
Evidence Basis
Fit
Profile
Primary Goal
Evidence Basis
Fit
Profile
Primary Goal
Evidence Basis
Fit
Section 03
How Larazotide Works
The mechanism is specific and well-characterized. Unlike most gut supplements that work indirectly through anti-inflammation or mucosal support, larazotide targets the molecular lock that opens tight junctions.
Tight Junctions: The Gut Gate
Intestinal tight junctions are protein complexes that seal the space between epithelial cells, preventing large molecules, bacteria, and antigens from crossing the gut barrier paracellularly. When tight junctions open inappropriately, the gut becomes permeable, allowing immune-activating content through.
Zonulin: The Opening Signal
Zonulin is released when gliadin or certain bacteria bind surface receptors on intestinal cells. It then binds the zonulin receptor and triggers a signaling cascade that redistributes tight junction proteins, widening the gaps. People with celiac disease have an exaggerated zonulin response.
Larazotide: Blocking the Lock
Larazotide binds the zonulin receptor on the apical surface of intestinal epithelial cells without activating it. By occupying the receptor, it prevents zonulin from binding and initiating the tight-junction-opening cascade. The junctions stay closed.
Minimal Systemic Absorption
Larazotide acts locally in the intestinal lumen. The Phase 1 pharmacokinetic study (Paterson 2007) confirmed very low plasma concentrations after oral dosing, consistent with luminal action rather than systemic distribution. This is a key safety advantage.
Section 04
What the Evidence Shows
Larazotide has more human evidence than almost any other compounded peptide available today. Reading that evidence carefully matters because the Phase 2b result is not a clean win.
| Study | Design | Key Finding | Strength |
|---|---|---|---|
| Paterson 2007 (APT) [5] | Phase 1, single-dose PK/safety, celiac patients | Safe and well-tolerated. Plasma levels were very low, confirming local luminal action. Proof of concept for gut-barrier effect. | Phase 1, Foundational |
| Kelly 2013 (APT) [2] | Phase 2 RCT, celiac patients undergoing supervised 6-week gluten challenge. 0.25 mg TID vs placebo. | Primary endpoint met: significantly lower GI symptom scores in the 0.25 mg group versus placebo during the gluten challenge. The 0.25 mg dose outperformed higher doses of 1 mg and 4 mg. | Phase 2, Positive |
| Leffler 2015 (Gastroenterology) [3] | Phase 2b RCT, 342 celiac patients on GFD with persistent symptoms. 0.5 mg TID for 12 weeks. | Primary composite GI symptom endpoint: narrowly missed significance (P = 0.059). Secondary endpoints: abdominal pain (P = 0.022), diarrhea, and celiac disease PRO measure were significantly improved vs placebo. | Phase 2b, Mixed |
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Section 05
Realistic Expectations
Larazotide works most reliably when there is an active zonulin signal to block, particularly around meals. Improvement, when it comes, is gradual reduction in gut symptoms over weeks rather than an immediate effect after the first dose.
Early Adaptation
Some patients notice mild improvement in bloating or diarrhea frequency within the first two weeks. Others feel no change yet. The primary Phase 2b benefit was measured over 12 weeks.
Barrier Stabilization
If larazotide is working, the most consistent early signals are reduced post-meal bloating, more predictable stool consistency, and reduced urgency. These correspond to the permeability reduction happening around each meal.
Symptom Plateau
The Phase 2b trial ran 12 weeks. Benefit that is going to occur should be apparent by this point. Reassess with your prescriber at week 8 to 12.
Maintenance vs Cycling
Larazotide addresses a receptor, not the underlying cause of elevated zonulin. In celiac disease, zonulin stays elevated because of immune reactivity to gliadin. In other conditions, the driver may be correctable. Long-term use should be periodically reassessed with your provider.
Section 06
Dosing Protocol
Larazotide is taken orally before meals because the permeability challenge occurs around eating. Timing and dose are derived from the Phase 2 trial protocols. The key finding from the dose-ranging study (Kelly 2013) was that 0.25 mg three times daily outperformed higher doses of 1 mg and 4 mg, an unusual dose-response that suggests the effective range is low.
| Context | Dose | Timing | Evidence Basis |
|---|---|---|---|
| Kelly 2013 Phase 2 (active gluten challenge) | 0.25 mg (250 mcg) | Three times daily, 30 min before meals | Phase 2, Best Dose in Trial |
| Leffler 2015 Phase 2b (persistent GFD symptoms) | 0.5 mg (500 mcg) | Three times daily, 30 min before meals | Phase 2b, Mixed Primary Endpoint |
| RxPepsDirect Standard (celiac or permeability focus) | Start 250 mcg TID | 30 min before each main meal, titrate to 500 mcg if needed | Clinical Practice |
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Optimal Balance Pharmacy fills larazotide as oral capsules in 250 mcg and 500 mcg strengths. The 250 mcg capsule three times daily (90 capsules per 30-day supply) is the starting protocol for most patients. If tolerated and partially effective, the prescriber may increase to 500 mcg TID. Beyond 0.5 mg TID, higher doses did not show additional benefit in the Phase 2 data and may be less effective than the low dose based on the Kelly 2013 dose-response.
Section 07
Ready to Take
No
Injection required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
180-day
Beyond Use Date on oral capsules
Section 08
Safety and Side Effects
Larazotide has a well-characterized tolerability profile from its Phase 2 program. The most notable finding is how clean the safety record is, given that this is a systemically minimally absorbed compound acting locally in the gut.
| Consideration | Detail | Action |
|---|---|---|
| Headache | The most common adverse event reported in Phase 2 trials, slightly more frequent in treated vs placebo groups in some analyses. | Usually mild and self-limited. Report persistent headache to your prescriber. |
| GI changes on starting | Some patients report transient changes in stool consistency in the first 1 to 2 weeks. | Typically resolves without stopping. If severe, contact your provider. |
| Drug interactions | Minimal systemic absorption means few systemic drug interaction concerns. Local gut interactions are theoretical but undocumented. | Disclose all medications to your prescriber at intake. |
| Pregnancy / lactation | No safety data in pregnancy | Avoid. |
| Long-term use | Trials ran 6 to 12 weeks. Long-term safety beyond that window is not formally characterized. | Periodic reassessment with your prescriber. Duration driven by ongoing clinical need. |
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Section 09
Stacking
Pairs Well With
BPC-157
Complementary mechanism: larazotide prevents barrier opening; BPC-157 promotes mucosal repair and angiogenesis after damage. Often combined for comprehensive gut support. BPC-157 is injectable or oral; no interaction concerns.
Thymosin Alpha-1
Immune modulation support. In autoimmune gut conditions where immune dysregulation and permeability overlap (celiac, IBD), Thymosin Alpha-1 addresses the immune component while larazotide addresses the barrier.
GHK-Cu
Anti-inflammatory and collagen-remodeling peptide. If mucosal integrity is part of the goal, GHK-Cu supports connective tissue health systemically. Separate timing, no interaction.
Avoid or Use Caution
Other zonulin-pathway agents at same meal
Theoretical concern only: other compounds that affect tight junction signaling taken simultaneously could confound the picture. No documented adverse interaction, but discuss any other gut-barrier agents with your prescriber.
Pregnancy
No safety data. Avoid.
Section 10
Pricing
Pharmacy: Medication
$1.80 per 250 mcg capsule / $3.50 per 500 mcg capsule. Compounded and dispensed by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. 180-day Beyond Use Date.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including GI history review, protocol design, dose selection, and prescription writing. Billed by RxPepsDirect for the medical service only.
Section 11
Legal Access in 28 States
503A Licensed Pharmacy
Optimal Balance Pharmacy, U.S. licensed
Physician Prescription Required
Compounded medication, Rx only
Phase 2 Evidence Base
No FDA approval, off-label prescribing
Off-Label, Legal Practice
Standard and legal in U.S. medicine
Larazotide reached Phase 2b clinical trials and has a substantial human safety and efficacy record, but it was never FDA-approved. In the United States it is available through 503A patient-specific compounding under a physician prescription. The 503A pathway is the documented legal route for compounded peptide access. RxPepsDirect prescribers serve patients in 28 states.
Section 12
Community Q&A
Does larazotide work for leaky gut in general, not just celiac disease?
The human trial evidence is celiac-specific. The mechanism supports use in any zonulin-driven permeability problem, but non-celiac conditions have not been tested in randomized trials. Mechanistically plausible, not evidence-validated outside celiac.
What did the big Phase 2b trial actually show?
342 celiac patients on a gluten-free diet with persistent symptoms. Twelve weeks of 0.5 mg TID. The primary composite GI symptom endpoint missed significance (P = 0.059). Secondary endpoints including abdominal pain and diarrhea were significant. It is a mixed result: not a clean win, but meaningful signals in a well-run trial.
Why does the lower dose (0.25 mg) seem to work better than higher doses?
The Kelly 2013 dose-ranging trial found that 0.25 mg TID outperformed 1 mg and 4 mg TID. This inverse dose-response is unusual. The leading explanation is receptor occupancy: at low concentrations larazotide acts as an antagonist at the zonulin receptor; at higher concentrations it may partially activate downstream signaling, reducing efficacy. This is why the starting dose is kept low.
Is larazotide absorbed into the bloodstream?
Minimally. The Phase 1 pharmacokinetic study showed very low plasma concentrations after oral dosing. Larazotide works locally in the intestinal lumen. This is a safety advantage, it does not circulate systemically in meaningful quantities.
Do I need to take it every day?
In the trials, larazotide was taken three times daily before meals every day for the course duration. Because permeability spikes occur around each meal, the pre-meal timing is part of the mechanism. An as-needed approach around known exposures (for example, a celiac patient before a restaurant meal) is sometimes used clinically, though the trials used daily continuous dosing.
Section 13
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your larazotide capsules under a patient-specific prescription with 503A oversight and a 180-day Beyond Use Date.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your gut health history, selects the appropriate dose (250 mcg vs 500 mcg), and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Efficacy Communication
This guide states plainly that the Phase 2b primary endpoint missed significance, that evidence is celiac-specific, and that non-celiac use is mechanistically supported but not trial-validated. We do not overstate the evidence.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011. PMID: 21248165
- Kelly CP, Green PH, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. 2013. PMID: 23163616
- Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015. PMID: 25701700
- Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci. 2012. PMID: 22731712
- Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007. PMID: 17207496
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
Recovery peptide protocol
BPC-157 protocol guide: clinical data, physician dosing, and the limits of the evidence
Mechanism, dosing, non-response rates, the angiogenesis question, WADA status, and the 503A pathway. Honest about what the human evidence is and is not.
Thymic immune peptide
Thymosin Alpha-1 protocol guide: T-cell maturation, the TESTS trial, and the chronic illness application
The 2025 TESTS sepsis trial failed. The hepatitis B evidence stays strong. ME/CFS, Long Lyme, Long COVID applications are mechanistically plausible. 20 to 30 percent non-responder rate.
Copper tripeptide (skin & tissue)
GHK-Cu protocol guide: collagen, the copper uglies, and the topical vs injectable evidence gap
Topical has human RCT support. Injectable for cosmetic claims is anecdotal. The copper uglies are real and manageable. Hair-loss support, yes; DHT blocker, no.
EPO-derived repair peptide protocol
ARA-290 (cibinetide) protocol guide: innate repair receptor, the neuropathy trials, and the non-erythropoietic difference
An 11-amino-acid fragment of erythropoietin that triggers tissue repair without EPO's blood-thickening effect. Human evidence is small Phase 2 neuropathy trials. Honest about where the data stops.
Continue reading